Suppr超能文献

嗜酸性食管炎成人及青少年吞咽困难症状问卷的心理测量评估

Psychometric evaluation of the Dysphagia Symptom Questionnaire for adults and adolescents with eosinophilic esophagitis.

作者信息

McCann Eilish, Peterson Kathryn A, Whalley Diane, Qin Shanshan, Tilton Sarette T, Kamat Siddhesh, Sun Xian, Dellon Evan S

机构信息

Regeneron Pharmaceuticals, Inc, Sleepy Hollow, NY.

University of Utah Health, Salt Lake City, Utah.

出版信息

J Allergy Clin Immunol Glob. 2024 Jul 16;3(4):100302. doi: 10.1016/j.jacig.2024.100302. eCollection 2024 Nov.

Abstract

BACKGROUND

Eosinophilic esophagitis (EoE) is a chronic, inflammatory disease of the esophagus leading to symptoms of esophageal dysfunction; dysphagia is the most common symptom experienced by adults and adolescents.

OBJECTIVE

We sought to perform a psychometric evaluation of the Dysphagia Symptom Questionnaire (DSQ), a patient-reported outcome measure for patients with EoE.

METHODS

Using baseline and week 24 data from the randomized, interventional, multinational phase 3 R668-EE-1774 trial (NCT03633617), the measurement properties of the DSQ-including reliability, construct and known-groups validity, responsiveness, and interpretation of change-were evaluated.

RESULTS

The analysis population comprised 239 patients with EoE (age [mean ± SD], 28.1 ± 13.14 years; 63.6% male; 90.4% White). Intraclass correlation coefficients of 0.92 and 0.97 exceeded the acceptable reliability threshold (≥0.70). Construct validity correlations with EoE symptom and impact measures were moderate at baseline (|| = 0.44-0.55) and week 24 (|| = 0.55-0.69), and the DSQ biweekly total score discriminated among groups defined by disease severity. Analyses exploring interpretation of change from baseline on the DSQ biweekly total score indicated thresholds for within-patient improvement ranging from 9 to 23 points; a within-patient improvement from baseline of 13 points or greater could be considered clinically meaningful.

CONCLUSIONS

This analysis confirmed that the DSQ has acceptable distributional properties, test-retest reliability, construct validity, and ability to detect change. Therefore, the DSQ is a valid and reliable measure to assess the patient-reported symptom of dysphagia among adult and adolescent patients with EoE in the context of a clinical trial setting.

摘要

背景

嗜酸性粒细胞性食管炎(EoE)是一种食管慢性炎症性疾病,可导致食管功能障碍症状;吞咽困难是成人和青少年最常见的症状。

目的

我们旨在对吞咽困难症状问卷(DSQ)进行心理测量学评估,这是一种针对EoE患者的患者报告结局指标。

方法

使用随机、干预性、多国3期R668-EE-1774试验(NCT03633617)的基线和第24周数据,评估DSQ的测量属性,包括信度、结构效度和已知组效度、反应性以及变化的解释。

结果

分析人群包括239例EoE患者(年龄[均值±标准差],28.1±13.14岁;63.6%为男性;90.4%为白人)。组内相关系数为0.92和0.97,超过了可接受的信度阈值(≥0.70)。在基线时(|| = 0.44 - 0.55)和第24周时(|| = 0.55 - 0.69),DSQ与EoE症状和影响指标的结构效度相关性为中等,并且DSQ双周总分在由疾病严重程度定义的组间存在差异。探索DSQ双周总分相对于基线变化解释的分析表明,患者内改善的阈值范围为9至23分;患者相对于基线改善13分或更多可被认为具有临床意义。

结论

该分析证实DSQ具有可接受的分布特性、重测信度、结构效度以及检测变化的能力。因此,在临床试验环境中,DSQ是评估成年和青少年EoE患者报告的吞咽困难症状的有效且可靠的指标。

相似文献

1
Psychometric evaluation of the Dysphagia Symptom Questionnaire for adults and adolescents with eosinophilic esophagitis.
J Allergy Clin Immunol Glob. 2024 Jul 16;3(4):100302. doi: 10.1016/j.jacig.2024.100302. eCollection 2024 Nov.
3
Validation of the novel Eosinophilic Esophagitis Impact Questionnaire.
J Patient Rep Outcomes. 2023 Nov 27;7(1):120. doi: 10.1186/s41687-023-00654-z.
5
Development and field testing of a novel patient-reported outcome measure of dysphagia in patients with eosinophilic esophagitis.
Aliment Pharmacol Ther. 2013 Sep;38(6):634-42. doi: 10.1111/apt.12413. Epub 2013 Jul 9.
7
Improvements in Dysphagia and Pain With Swallowing in Patients With Eosinophilic Esophagitis Receiving Budesonide Oral Suspension.
Clin Gastroenterol Hepatol. 2021 Apr;19(4):699-706.e4. doi: 10.1016/j.cgh.2020.03.060. Epub 2020 Apr 6.
9
Pooled Phase 2 and 3 Efficacy and Safety Data on Budesonide Oral Suspension in Adolescents with Eosinophilic Esophagitis.
J Pediatr Gastroenterol Nutr. 2023 Dec 1;77(6):760-768. doi: 10.1097/MPG.0000000000003948. Epub 2023 Sep 18.

引用本文的文献

1
Patient-Reported Outcome Measures in Benign Esophageal Disorders.
Am J Gastroenterol. 2025 Apr 7. doi: 10.14309/ajg.0000000000003467.

本文引用的文献

1
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis.
N Engl J Med. 2022 Dec 22;387(25):2317-2330. doi: 10.1056/NEJMoa2205982.
3
Determination of a treatment response threshold for the Eosinophilic Esophagitis Endoscopic Reference Score.
Endoscopy. 2022 Jul;54(7):635-643. doi: 10.1055/a-1675-7860. Epub 2022 Jan 11.
4
Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results from a Phase 3 Trial.
Clin Gastroenterol Hepatol. 2022 Mar;20(3):525-534.e10. doi: 10.1016/j.cgh.2021.04.022. Epub 2021 Apr 19.
6
Epidemiology and risk factors for eosinophilic esophagitis: lessons for clinicians.
Expert Rev Gastroenterol Hepatol. 2020 Nov;14(11):1069-1082. doi: 10.1080/17474124.2020.1806054. Epub 2020 Aug 24.
7
Symptom-based diagnostic approach for eosinophilic esophagitis.
J Gastroenterol. 2020 Sep;55(9):833-845. doi: 10.1007/s00535-020-01701-y. Epub 2020 Jul 27.
8
Improvements in Dysphagia and Pain With Swallowing in Patients With Eosinophilic Esophagitis Receiving Budesonide Oral Suspension.
Clin Gastroenterol Hepatol. 2021 Apr;19(4):699-706.e4. doi: 10.1016/j.cgh.2020.03.060. Epub 2020 Apr 6.
9
Eosinophilic esophagitis: early diagnosis is the key.
Clin Exp Gastroenterol. 2019 Aug 15;12:391-399. doi: 10.2147/CEG.S175061. eCollection 2019.
10
Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial.
Gastroenterology. 2019 Jul;157(1):65-73.e5. doi: 10.1053/j.gastro.2019.03.014. Epub 2019 Mar 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验